Switzerland· 67534001
Entyvio subkutan
A vedolizumab product containing vedolizumabum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Vedolizumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AG05 (vedolizumab), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 8 of them publish a price we can compare per daily dose
Vedolizumab · ATC L04AG05
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of vedolizumab costs, country by country.
Normalised to the WHO defined daily dose (5.4 mg), so markets compare like for like.
- Switzerland: $36.68 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Vedolizumab · price per daily dose (5.4 mg)
USD · FX 28 Sept 2026
- CH Switzerland$36.68
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- vedolizumabum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- L04AG05
- ATC class
- Vedolizumab
- Defined daily dose
- 5.4 mg, P
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680675340019Fertpen 1 StkCHF 608.35
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
60 interactions on record for vedolizumab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Vedolizumab · interactions on record
60 records
- 27 severe
- 26 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Vedolizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandEntyvio2care4 ApS
- CzechiaENTYVIOTakeda Pharma A/S, Vallensbaek Strand
- SpainENTYVIO 108 MG SOLUCION INYECTABLE EN JERINGA PRECARGADATakeda Pharma A/S
- United KingdomEntyvio 108mg/0.68ml solution for injection pre-filled pensTakeda UK Ltd
- United StatesEntyvioTakeda Pharmaceuticals America, Inc.
- CanadaENTYVIOTAKEDA CANADA INC
- FranceENTYVIO 108 mg, solution injectable en seringue préremplieTAKEDA PHARMA (DANEMARK)
- NetherlandsEntyvio 108 mg, oplossing voor injectie in voorgevulde penTakeda Pharma A/S
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Entyvio
- Liechtenstein · Entyvio
- Norway · Entyvio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6ea70f94-ba38-40b4-844c-793bce44eff2 GET /v1/drugs/6ea70f94-ba38-40b4-844c-793bce44eff2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "vedolizumabum 108 mg",
"valid_from": "2021-03-01",
"limitations": "[{\"description\":\"Zur Behandlung von Erwachsenen von mittel- bis hochgradig aktiver Colitis ulcerosa und mittel- bis hochgradig aktivem Morbus Crohn, die auf die Standardtherapie oder einen Antagonisten von Tumornekrosefaktor alpha (TNFα) nicht ausreichend oder nicht mehr ansprachen oder Unverträglichkeit zeigten.<br> \\nEine Umstellung auf Entyvio subkutan (subkutanes Vedolizumab) als Erhaltungstherapie erfolgt nach mindestens 2 intravenösen Infusionen von Entyvio. Eine Weiterbehandlung nach einer Therapie mit Entyvio von einem Jahr bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\n<br>\",\"costApproval\":null,\"indication\":null,\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2021-03-01\",\"validTo\":null}]",
"galenic_form": "Inj Lös 108 mg/0.68ml Fertigpen",
"therapeutic_area": null,
"sl_inclusion_date": "2021-03-01",
"self_retention_pct": 10
}See everything about vedolizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.